A randomized trial comparing mebendazole and secnidazole for the treatment of giardiasis

Ann Trop Med Parasitol. 2003 Jul;97(5):499-504. doi: 10.1179/000349803235002380.

Abstract

To compare the efficacy of the two drugs in the treatment of giardiasis, 146 children (aged 5-15 years) with confirmed Giardia lamblia infection were randomly allotted to treatment with mebendazole (200 mg three times daily for 3 days) or secnidazole (30 mg/kg, in a single dose). Parasitological response to treatment was evaluated in each child by the microscopical examination of faecal samples collected 3, 5 and 7 days after he or she had completed treatment. Although the frequency of cure was higher for secnidazole (79.4%) than for mebendazole (78.1%), the difference was not statistically significant (P > 0.05). Both treatment regimens were well tolerated, with only mild, transient and self-limiting side-effects reported. Mebendazole may be preferable to secnidazole in the treatment of giardiasis cases who have an history of intolerance to 5-nitromidazoles, and where infections with Giardia and soil-transmitted helminths frequently co-occur.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Antiprotozoal Agents / adverse effects
  • Antiprotozoal Agents / therapeutic use
  • Child
  • Child, Preschool
  • Feces / parasitology
  • Female
  • Giardiasis / drug therapy*
  • Giardiasis / parasitology
  • Humans
  • Male
  • Mebendazole / adverse effects
  • Mebendazole / therapeutic use*
  • Metronidazole / adverse effects
  • Metronidazole / analogs & derivatives*
  • Metronidazole / therapeutic use*
  • Treatment Outcome

Substances

  • Antiprotozoal Agents
  • Metronidazole
  • Mebendazole
  • secnidazole